Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanjing Medical To Build Health Care Industrial Park

This article was originally published in PharmAsia News

Executive Summary

Nanjing Medical Company has signed a 20-year real estate and land lease with Nanjing Compressor Co., Ltd. According to the contract, Nanjing Compressor will lease its number one production zone including all buildings, auxiliary equipment, facilities, fittings and land to Nanjing Medical at a total of 229.19 million yuan for the next 20 years. Nanjing Medical is to put in 5.5 million yuan for 55 percent equity of a new management company, which will be set up to oversee construction of the industrial park. With its focus on integrating logistics resources, Nanjing Medical is looking for investors to develop the municipal park into a center for high-end preventive medicine, health care and rehabilitation, business, product R&D and modern logistics. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel